

## Schriftenverzeichnis

### Originalarbeiten (Erstautor, Seniorautor, Co-Autor)

Reichrath S, Müller CS, Gleissner B, Pfreundschuh M, Vogt T, Reichrath J. Notch- and vitamin D signaling in 1,25(OH)<sub>2</sub>D<sub>3</sub>-resistant glioblastoma multiforme (GBM) cell lines. **J Steroid Biochem Mol Biol**. 2010 Jul;121(1-2):420-4. Epub 2010 Mar 4. Impact Faktor

Hess S., Pfreundschuh M, Gleissner B. Notch signaling. **J Neuro-Surg**, 2007; 107(5):1060-1. **Impact Faktor 2.242**

Gleissner B, Chamberlain MC. Treatment of CNS dissemination in systemic lymphoma. **J Neuro-Oncology** 2007; 5(5):443-452, **Impact Faktor 1,848**.

Pagano L, Gleissner B, Fianchi L. Breakthrough zygomycosis and voriconazole. **Journal of Infectious Diseases**, 2005; 192: 1496-7. **Impact Faktor 6,186**.

Gleissner B, Goekbuget N, Rieder H, Schwartz S, Diedrich H, Arnold R, Schoch C, Heinze B, Fonatsch C, Bartram CR, Hoelzer D, Thiel E, for the GMALL Study Group. CD10-negative pre-B acute lymphoblastic leukemia (ALL): a distinct high-risk subgroup of adult ALL. Results of the German Multicenter Trials for Adult ALL (GMALL). **Blood**, 2005: 106: 4054-6. **Impact Faktor 10,320**.

Gleissner B, Schilling A, Anagnostopopoulos I, Siehl J, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? **Leukemia & Lymphoma** 2004; 45(7): 1351-1360. **Impact Faktor: 1,559**

Gleissner B, Goekbuget N, Bartram CR, Janssen B, Rieder H, Janssen JWG, Fonatsch C, Heyll A, Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E, the GMALL study group. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study by confirmed polymerase chain reaction (PCR) analysis of the German Multicenter Trial Group. **Blood** 2002;99(5):1536-1543. **Impact Faktor: 10,320**.

Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. **Neurology** 2002; 58(3): 390-396. **Impact Faktor: 5,690**.

Gleissner B, Blau IW, Sindram A, Reinhardt R, Knauf W, Thiel E. Analysis of chimerism during the early period after allogeneic peripheral stem cell transplantation. **Clinical & Laboratory Haematology** 2001; 23: 401-406. **Impact Faktor: 0,921**.

Gleissner B, Rieder H, Thiel E, Fonatsch Ch, Janssen LAJ, Heinze B, Janssen JWG, Schoch C, Goekbuget N, Maurer J, Hoelzer D, Bartram CR. Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data. **Leukemia** 2001;15: 1834-1840. **Impact Faktor: 6,146.**

Gleissner B, Maurer J, Sindram A, Reinhardt R, Thiel E. Comparison of ethidium bromide-stained agarose gel electrophoresis and automated fragment analysis for evaluation of IgH gene products. **Leukemia Research** 2001; 25: 796-774. **Impact Faktor: 2,483.**

Gleissner B, Maurer J, Thiel E. Detection of immunoglobulin heavy chain genes rearrangements in B-cell leukemias, lymphomas, multiple myelomas, monoclonal and polyclonal gammopathies. **Leukemia & Lymphoma** 2000; 39(1/2): 151-155. **Impact Faktor: 1,559.**

Gleissner B, Hellmann A, Berdel WE, Edler L, Koldehoff M, Rost A, Opri F, Fritze D, Öhl S. Phase I/II study of paclitaxel and 5-fluorouracil as second-line therapy in patients with metastatic breast cancer. **Onkologie** 1998; 21: 305-308. **Impact Faktor: 1,724.**  
Wadler S, Gleissner B, Hilgenfeld RU, Thiel E, Hayner H, Kaleya R, Rozenblit A, Kreuser E.D. Phase II study of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon  $\alpha$ -2b in patients with advanced gastric carcinoma. **European Journal of Cancer** 1996; 324(7): 1254-1256. **Impact Faktor: 4,167.**

Kölble K, Gleissner B, Diepgen T, Stöcker W, Mohr C, Kalies I, Druschky K-F, Kalden JR. Complotypes of the major histocompatibility complex linked class III genes in Myasthenia gravis. **Annals New York Academy of Science** 1987; 505: 792-796. **Impact Faktor: 1,789.**

### **Fallberichte (peer reviewed)**

Schilling A, Seibold M, Mansman V, Gleissner B. Successfully treated *Candida krusei* infection of the lumbar spine with combined caspofungin/posaconazole therapy. **Med. Mycol** 2008;46(1):79-83. **Impact Faktor 2.6**

Mailander V, Gleissner B, Blau I, Thiel E. Guillain-Barre-Strohl syndrome unraveled as paraneoplastic syndrome of B-cell acute lymphoblastic leukemia in a patient with preceding common variable immunodeficiency syndrome with Evans syndrome. **Leukemia & Lymphoma** 2004; 45(1):189-92. **Impact Faktor: 1,147.**

## **Reviews**

Gleissner B., Zwick C, Pfreundschuh M. Behandlung diffus großzelliger Non-Hodgkin Lymphom. **Deutsche Medizinische Wochenschrift**, 2008 Sep;133(36):1785-94; quiz 1795-6. Epub 2008 Sep 2. Review. German. **Impact Faktor 0,584**

Zwick C, Gleissner B., Pfreundschuh M. Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma. **Clin Lymphoma Myeloma** 2007; 8(2):43-9. **Impact Faktor 2,444**

Gleissner B., Küppers M, Siebert R, et al. Report on a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. **Brit J Haematology**, 2008, Epub ahead, **Impact Faktor 4,498**

Gleissner B., Zwick C, Pfreundschuh M. Treatment of aggressive lymphomas. **Internist**, 2007, 48(4):389-95. **Impact Faktor 0,277**

Gleissner B., Schlenk R, Bornhäuser M, Berdel WE. Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia-ongoing trials. **Onkologie** 2007; 30(12): 657-62. **Impact Faktor 1,724**

Thiel E, Gleissner B. Meningeosis neoplastica, **Deutsches Ärzteblatt**, 2006; 39: 2559-2565.

Gleissner B., Chamberlain MC. Meningeosis neoplastica. **Lancet Neurology** 2006; 5(5):443-452, **Impact Faktor 9,479**.

Gleissner B., Hoelzer D, Thiel E. Therapie der Meningeosis neoplastica. **journalONKOLOGIE** 2005; 4, 40-46.

Gleissner B., Thiel E. Molecular genetic events in adult acute lymphoblastic leukemia. **Expert Review of Molecular Diagnostics** 2003; 3(3): 89-105. **Impact Faktor 2,348**

Gleissner B., Thiel E. Detection of immunoglobulin heavy chain (IgH) gene rearrangements in hematologic malignancies. **Expert Review of Molecular Diagnostics** 2001; 1(2): 191-2001. **Impact Faktor: 2,348**

### **Buchbeiträge**

Gleissner B., Pfreunds Schuh M. Myelodysplasie und Chronisch Myeloische Leukämie in Entscheidungsprozesse Innere Medizin, Hrsg. Brunkhorst, in press

Gleissner B., Pfreunds Schuh M. Akute Leukämien. In Compedium Onkologie, Herausgeber Preiss, 2008.

Gleissner B., Pfreunds Schuh M. Therapeutische Ansätze zur Behandlung hochmaligner Lymphoma. Colloquium Onkologie, 2007.

Gleissner B., Zwick C., Pfreunds Schuh M. Therapie aggressiver Lymphome, In „Lymphomtherapie“, Herausgeber Rummel, Reihe UniMed Verlag, 2007.

Thiel E, Gleissner B. Ätiologie und Pathogenese. In Akute lymphatische Leukämie des Erwachsenen. Reihe UNI-MED Verlag, 2007.

Gleissner B., Bartram CR, Rieder H, Janssen LAJ, Janssen JWG, Goekbuget N, Hoelzer D, Fonatsch C, Heinze B, Schoch C, Thiel E. Reliability of BCR-ABL RT\_PCR in adult acute B-lineage lymphoblastic leukemia: results of confirmatory PCR. In Acute Leukemia IX, Hiddemann W, Büchner T, Ritter J, Unterhalt M, Haferlach T (Eds.) Springer Verlag, 2003:338-341.